MedTrace Logo

Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

NCT00447837 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2008-03-17

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety and efficacy of SPRC-AB01 versus placebo for treatment of chronic sinusitis in subjects who have had sinus surgery.

Conditions

  • Chronic Sinusitis

Interventions

DRUG

SPRC-AB01

90 mg/3 mL BID, 180 mg/3 mL bid, placebo

Sponsors & Collaborators

  • Naryx Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-12-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447837 on ClinicalTrials.gov